Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
01167 JACOBIO-B
4.190
-0.100-2.33%
YOY
Do not show
Hide blank lines
(Q6)2022/06/30(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31
Turnover
-5.20% 54.69M -68.58% 152.81M -- 57.69M -- 486.29M
Operating income
-5.20% 54.69M -68.58% 152.81M 57.69M 486.29M
Cost of sales
13.70% -45.85M -217.30% -139.98M -- -53.13M -- -44.12M
Operating expenses
13.70% -45.85M -217.30% -139.98M -53.13M -44.12M
Gross profit
93.88% 8.83M -97.10% 12.83M 4.56M 442.17M
Administrative expenses
-22.94% -22.78M 17.20% -44.58M -49.73% -18.53M 24.26% -53.84M
Research and development expenses
-45.15% -176.59M -51.03% -280.84M -71.32% -121.66M -33.80% -185.95M
Special items of operating profit
763.63% 55.12M 70.79% -6.8M -286.69% -8.31M -246.47% -23.27M
Operating profit
5.92% -135.41M -278.32% -319.38M -82.35% -143.94M 192.24% 179.11M
Financing income
0.93% 7.72M 496.85% 18.77M 317.48% 7.64M -41.04% 3.14M
Financing cost
58.42% -126K 62.06% -568K 57.86% -303K -8.95% -1.5M
Special items of earning before tax
-- -- -- -- -- -- -619.18% -1.69B
Earning before tax
6.42% -127.83M 80.10% -301.19M 83.15% -136.6M -255.48% -1.51B
After-tax profit from continuing operations
6.42% -127.83M 80.10% -301.19M 83.15% -136.6M -255.48% -1.51B
Earning after tax
6.42% -127.83M 80.10% -301.19M 83.15% -136.6M -255.48% -1.51B
Minority profit
-- -- -- -- -- -- 97.81% -22K
Profit attributable to shareholders
6.42% -127.83M 80.10% -301.19M 83.15% -136.6M -256.31% -1.51B
Basic earnings per share
5.56% -0.17 89.92% -0.4 92.56% -0.18 -104.64% -3.97
Diluted earnings per share
5.56% -0.17 89.92% -0.4 92.56% -0.18 -104.64% -3.97
Currency Unit
CNYCNYCNYCNY
Accounting Standards
IASIASIASIAS
Audit Opinions
--Unqualified Opinion--Unqualified Opinion
Auditor
--PricewaterhouseCoopers--PricewaterhouseCoopers

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Jiakos Pharmaceutical Group Co., Ltd. is committed to providing breakthrough treatment solutions for patients, and the company's vision is to work with partners to become a globally recognized leader in drug research and development. The company's laboratories are located in Beijing, China and Massachusetts, USA, and the experimental platform has allosteric inhibitors for the development of protein phosphatase, KRAS and other transcription factors. Garkos has received investment from several biotechnology investment institutions, including QiMing Venture Partners, Lilly Asia Fund, Hillhouse and Taiwan Yusheng.
CEO: Yinxiang Wang
Market: Hong Kong motherboard
Listing Date: 12/21/2020
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist